Minoryx Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for orphan CNS diseases with high unmet medical need. The company's lead product candidate, MIN-102, is a novel, brain-penetrant and selective PPAR gamma agonist that is being developed for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare and life-threatening genetic disorder that affects the central nervous system. MIN-102 has received orphan drug designation from both the FDA and the EMA, and fast track and rare pediatric disease designation from the FDA. Minoryx is also developing MIN-102 for the treatment of other orphan CNS diseases, including adrenomyeloneuropathy (AMN) and Krabbe disease.

Minoryx was founded in 2011 by a team of experienced scientists and clinicians with a passion for developing new treatments for patients with rare diseases. The company is headquartered in Mataró, Spain, and has offices in Cambridge, Massachusetts.

Minoryx is committed to making innovative treatments available for patients suffering from life-threatening orphan diseases. The company is working to advance MIN-102 through clinical development and to bring it to market as soon as possible.

Here are some additional details about Minoryx:
-Founded in 2011
-Headquarters in Mataró, Spain
-Offices in Cambridge, Massachusetts
-Team of experienced scientists and clinicians